Could a common diabetes pill ease long COVID?
NCT ID NCT06907251
First seen Feb 23, 2026 · Last updated May 09, 2026 · Updated 7 times
Summary
This study tests whether dapagliflozin, a drug used for diabetes, can improve quality of life in people with long COVID. About 192 adults with persistent symptoms after a COVID-19 infection will receive either the drug or a placebo for 12 months. The main goal is to see if the drug helps with overall well-being and reduces complications like diabetes or heart problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Ottawa Heart Institute
Ottawa, Ontario, K1Y 4W7, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.